- Author: Burke A Cunha, MD; Chief Editor: Michael Stuart Bronze, MD more...
Babesiosis is a tick-borne malaria-like illness caused by species of the intraerythrocytic protozoan Babesia. Humans are opportunistic hosts for Babesia when bitten by nymph or adult ticks. Currently, Babesia infection is transmitted by various tick vectors in Europe, Asia, and the northwestern and northeastern United States.
Human babesiosis is a zoonotic infection in which ticks transmit Babesia organisms from a vertebrate reservoir to humans[1, 2] ; the infection is incidental in humans. The primary Babesia species that infect cattle include Babesia divergens, Babesia bigemina, Babesia bovis, and Babesia major. In horses, the main species is Babesia equi. Babesia canis is the primary species in dogs, and Babesia felis is the main species in cats. Babesia microti is the species found in mice.
Babesia species and organisms of the closely related genus Theileria have worldwide distribution, parasitizing the erythrocytes of wild and domestic animals. These parasites are commonly called piroplasms because of the pear-shaped forms found within infected red blood cells (RBCs). Most human babesial infections are caused by B microti (found only in the United States) or by B divergens and B bovis (found only in Europe).
Human babesiosis is infrequent and occurs in limited geographic locations. In the United States, it is usually an asymptomatic infection in healthy individuals. Several groups of patients become symptomatic, and, within these subpopulations, significant morbidity and mortality occur. The disease most severely affects patients who are elderly, immunocompromised, or asplenic.
Babesiosis is difficult to diagnose. Although the index of suspicion should be high in areas endemic for Babesia infection, patients with babesiosis have few, if any, localizing signs to suggest the disease. Confirmation of the diagnosis depends on the degree of parasitemia and the expertise and experience of the laboratory personnel.
Most patients infected by B microti who are otherwise healthy appear to have a mild illness and typically recover without specific chemotherapy; however, treatment is recommended for all diagnosed cases to prevent sequelae and potential transmission through blood donation. In addition, patients should be advised to take precautions against tick exposure and to refrain from donating blood until completely cured of babesiosis.
Babesiosis is a zoonotic disease maintained by the interaction of tick vectors, transport hosts, and animal reservoirs. The primary vectors of the parasite are ticks of the genus Ixodes. In the United States, the black-legged deer tick, Ixodes scapularis (also known as Ixodes dammini; see the image below), is the primary vector for the parasite; in Europe, Ixodes ricinus appears to be the primary tick vector. In each location, the Ixodes tick vector for Babesia is the same vector that locally transmits Borrelia burgdorferi, the agent implicated in Lyme disease.
I scapularis has 3 developmental stages—larva, nymph, and adult—each of which requires a blood meal for development into the next stage. As a larva and nymph, the tick feeds on rodents (eg, the white-footed mouse, Peromyscus leucopus); however, as an adult, the tick prefers to feed on the white-tailed deer. Female ticks are impregnated while obtaining their blood meal on the deer, with the formation of up to 20,000 eggs. (In Europe, by way of contrast, cattle constitute the primary animal reservoir).
The clinical signs and symptoms of babesiosis are related to the parasitism of RBCs by Babesia. The ticks ingest Babesia from the host during feeding; they then multiply the protozoa in their gut wall and concentrate them in their salivary glands. When they feed again on a new host, they inoculate the new host with Babesia.
Entering the host’s bloodstream during the tick bite, the parasite infects RBCs, and differentiated and undifferentiated trophozoites are produced. Upon infection of the host erythrocyte, mature B microti trophozoites undergo asynchronous asexual budding and divide into 2 or 4 merozoites. As parasites leave the erythrocyte, the membrane is damaged. The precise mechanism of hemolysis is unknown.
Babesia species in the host erythrocyte range from 1 to 5 µm in length. B microti measures 2 × 1.5 µm, B divergens measures 4 × 1.5 µm, and B bovis measures 2.4 × 1.5 µm. As noted, the organisms are pear-shaped, oval, or round. Their ring form and peripheral location in the erythrocyte frequently lead to their being mistaken for Plasmodium falciparum. However, they differ from P falciparum in that the schizogony is asynchronous and massive hemolysis does not occur.
Alterations in RBC membranes cause decreased conformability and increased RBC adherence, which can lead to development of noncardiac pulmonary edema and acute respiratory distress syndrome (ARDS) among those severely affected.
Fever, hemolytic anemia, and hemoglobinuria may result from Babesia infection. As with malaria, RBC fragments may cause capillary blockage or microvascular stasis, which explains liver, splenic, renal, and central nervous system (CNS) involvement. As with malaria, cells of the reticuloendothelial system (RES) in the spleen remove damaged RBC fragments from the circulation. RBC destruction results in hemolytic anemia.
The spleen offers a critical host defense against babesiosis, as suggested by the higher incidence and greater severity of babesiosis in asplenic patients. The spleen traps the infected erythrocytes, and their ingestion by the macrophages follows.
Complement activation by Babesia may lead to the generation of tumor necrosis factor (TNF) and interleukin-1 (IL-1). Decreased complement levels, increased circulating C1q-binding activity, and decreased C4, C3, and CH50 levels are observed in patients with babesiosis. The generation of these primarily macrophage-produced mediators may explain many of the clinical features, such as fever, anorexia, arthralgias, myalgias, and the fulminant shock syndrome of bovine babesiosis.
Babesiosis elicits a B-cell response and a T-cell response. Patients with acute babesiosis have an increase in T-suppressor lymphocytes, T-cytotoxic lymphocytes, or both and decreased responses to lymphocyte mitogens with a polyclonal hypergammaglobulinemia.
Babesiosis is an infection caused by parasites of the Babesia genus. It is a zoonosis that is transmitted from vertebrates to humans through the bite of a tick from the Ixodidae family (I scapularis in the United States, I ricinus in Europe). Ixodes ticks are small and differ from the large Dermacentor ticks that transmit Rocky Mountain spotted fever (RMSF) and ehrlichiosis.
More than 100 species of Babesia exist, but only a small number of them are known to be responsible for the majority of symptomatic disease. The causative agent of babesiosis varies according to geographic region.
In the United States, human infection with Babesia is primarily due to the rodent strain B microti, found mostly in northeastern and midwestern states. A few cases have been reported in Missouri, California, and Washington and are found to be caused by Babesia -like agents named after their geographic location: MO-1 (Missouri; closely related to B divergens), CA-1 (California), and WA-1 (Washington; also known as CA5 and Babesia duncani).
In Europe, the causative agent of babesiosis is typically the cattle strain B divergens, though B microti and B microti -like agents have been identified. Another cattle strain found in Europe, B bovis, also causes disease in humans on occasion.
Tick life cycle
The I scapularis life cycle requires 2 years for completion, beginning from egg deposition in the spring. The white-footed mouse is the primary enzootic reservoir. After feeding on infected white-footed mice, the tick larvae become infected with B microti. The tick larvae are maintained as the tick develops from the larval phase to the nymphal phase. This development takes 1 year (ie, until the next spring).
Nymphs infected with B microti may transmit the Babesia organisms to other mice or rodents or to a human host. Nymphs feed for 3-4 days on white-footed mice or rodents and mature into adults the following fall.
Adult Ixodes tick populations are maintained in white-tailed deer. The adults mate and feed on the deer during the spring; they then deposit their eggs and die. The white-footed mouse is necessary to perpetuate the Babesia organisms, and the deer is needed to perpetuate the Ixodes tick population.
Larvae, nymphs, and adult ticks all may infect humans, but the nymph is the primary vector of B microti infection in humans.
Babesia parasites from rodents (primarily the white-footed deer mouse but also the field mouse, vole, rat, and chipmunk) are transmitted to humans during tick bites in endemic areas. Babesiosis is understandably more prevalent during the periods of tick activity, such as spring and summer.
Although rodents are infected with Babesia, the white-tailed deer does not carry the organism. B microti is transmitted from the larval phase of I scapularis to the nymphal phase (transstadial transmission) but not transovarially. Human infection is primarily produced by the bite of an infected nymph during a blood meal. Restocking of deer populations and curtailment of hunting has increased deer herds in certain areas. The proximity of deer, mouse, and tick create the conditions for human infection.
Several reported cases of infection via blood transfusions from donors who lived in or traveled to an endemic area have been documented.[3, 4] All of these cases have occurred in the United States, with the exception of 1 patient in Canada (acquired from a donor who became infected while in the United States) and 1 in Japan. The incubation period in transfusion-associated disease appears to be 6-9 weeks. The rate of acquiring B microti from a unit of packed RBCs has been estimated to be 1 in 600-1800 in endemic areas.
Case reports of transplacental or perinatal transmission have been documented. Transplacental transmission has also occurred rarely.
United States statistics
Human babesiosis is endemic in the northeastern coastal region of the United States, particularly Nantucket Island, Martha’s Vineyard, and Cape Cod (Massachusetts); Block Island (Rhode Island); and eastern Long Island, Shelter Island, and Fire Island (New York). Disease prevalence in Cape Cod, as suggested by antibody to B microti, has been reported as 3.7%, whereas on Shelter Island in individuals with a high risk of exposure to ticks, it was 4.4% in June and reached 6.9% by October.
Cases have also been reported from the Connecticut mainland and Washington State. In addition, infections with Babesia species have been reported in New Jersey, Maryland, Virginia, California, Wisconsin, Minnesota, Missouri, Georgia, and Mexico.
An increasing trend over the past 30 years may be the result of restocking of the deer population, curtailment of hunting, and an increase in outdoor recreational activities. Between 1968 and 1993, more than 450 cases of Babesia infections were confirmed in the United States. However, the actual prevalence of this disease is unknown because most infected patients are asymptomatic.
In endemic areas, the organism may also be transmitted by blood transfusion.[6, 7, 8, 9, 10, 11]
Babesiosis occurs in areas of Europe and Asia, where the tick vector and vertebrate host reside, and it occurs in healthy as well as asplenic persons. On the whole, however, it is rare in Europe. Since 1957, when the first case of human babesiosis was reported in an asplenic farmer from the former Yugoslavia, approximately 40 cases have been reported, mostly in Ireland, the United Kingdom, and France. All of the cases involved bovine Babesia and occurred in individuals who were splenectomized.
Sporadic case reports of babesiosis in Japan, Korea, China, Mexico, South Africa, and Egypt have also been documented. One report describes human Babesia infection in Columbia.
Age-, sex-, and race-related demographics
Although persons of any age can be affected by babesiosis, clinically ill patients with intact spleens are usually aged 50 years or older, which suggests that age plays a factor in the severity of the clinical response. Patients with babesiosis who were previously healthy individuals are generally older (mean, >60 years) than those who had previous medical problems (mean, 48 years). Vannier et al suggested that the age-associated decline in resistance to B microti is genetically determined.[1, 2]
Babesiosis has no predilection for sex or race.
Babesiosis has a spectrum of severity, which may be divided into 3 distinct parts as follows :
A mild-to-moderate viral-like syndrome
Severe disease with a fulminant course resulting in death or a persistent relapsing course
Babesiosis in otherwise healthy hosts produces an acute infectious disease that resembles malaria. Most cases of babesiosis are subclinical or are mildly symptomatic. Babesiosis may continue for more than 2 months after treatment; asymptomatic infections can persist silently for months to years. Patients with positive smears or positive polymerase chain reaction (PCR) test results more than 3 months after initial treatment should be treated again, regardless of the presence or absence of seizures.
In healthy individuals with intact spleens, babesiosis is rarely fatal; however, in patients who are asplenic, babesiosis is generally quite severe and is associated with substantial mortality. Asplenic patients have a more fulminant and prolonged clinical course and may have overwhelming infection that results in death. In a 1998 review by White et al, 9 of 139 (6.5%) patients who were hospitalized with babesiosis in New York State from 1982-1983 died.
In the United States, the prognosis for babesiosis is excellent; most patients recover spontaneously. About 25% of adults and 50% of children infected with Babesia are asymptomatic, improve spontaneously without treatment, or both. Fewer than 10% of US patients with babesiosis have died, and most of these have been elderly or asplenic.
In Europe, however, babesiosis is a life-threatening disease. Most symptomatic European patients are asplenic, which contributes to a poor prognosis. More than 50% of patients with babesiosis in Europe become comatose and die. About 83% of infected patients are asplenic.
Deaths have been reported from transfusion-transmitted babesiosis within the immunocompromised population in areas where Babesia infection is not endemic.
Approximately 20% of patients with babesiosis are co-infected with Lyme disease. The symptoms experienced by these patients are more severe symptoms and last longer than those experienced by patients who have either disease alone.
Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am. 2008 Sep. 22(3):469-88, viii-ix. [Medline].
Joseph JT, Roy SS, Shams N, Visintainer P, Nadelman RB, Hosur S, et al. Babesiosis in Lower Hudson Valley, New York, USA. Emerg Infect Dis. 2011 May. 17(5):843-7. [Medline].
Dobroszycki J, Herwaldt BL, Boctor F, Miller JR, Linden J, Eberhard ML, et al. A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor. JAMA. 1999 Mar 10. 281(10):927-30. [Medline].
Gerber MA, Shapiro ED, Krause PJ, Cable RG, Badon SJ, Ryan RW. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis. 1994 Jul. 170(1):231-4. [Medline].
Jacoby GA, Hunt JV, Kosinski KS, Demirjian ZN, Huggins C, Etkind P, et al. Treatment of transfusion-transmitted babesiosis by exchange transfusion. N Engl J Med. 1980 Nov 6. 303(19):1098-100. [Medline].
Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang. 2006 Apr. 90(3):157-65. [Medline].
Mintz ED, Anderson JF, Cable RG, Hadler JL. Transfusion-transmitted babesiosis: a case report from a new endemic area. Transfusion. 1991 May. 31(4):365-8. [Medline].
Wittner M, Rowin KS, Tanowitz HB, Hobbs JF, Saltzman S, Wenz B, et al. Successful chemotherapy of transfusion babesiosis. Ann Intern Med. 1982 May. 96(5):601-4. [Medline].
Wormser GP, Lombardo G, Silverblatt F, El Khoury MY, Prasad A, Yelon JA, et al. Babesiosis as a cause of fever in patients undergoing a splenectomy. Am Surg. 2011 Mar. 77(3):345-7. [Medline].
White DJ, Talarico J, Chang HG, Birkhead GS, Heimberger T, Morse DL. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med. 1998 Oct 26. 158(19):2149-54. [Medline].
Gubernot DM, Lucey CT, Lee KC, Conley GB, Holness LG, Wise RP. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis. 2009 Jan 1. 48(1):25-30. [Medline].
Kuwayama DP, Briones RJ. Spontaneous splenic rupture caused by Babesia microti infection. Clin Infect Dis. 2008 May 1. 46(9):e92-5. [Medline].
Froberg MK, Dannen D, Bernier N, Shieh WJ, Guarner J, Zaki S. Case report: spontaneous splenic rupture during acute parasitemia of Babesia microti. Ann Clin Lab Sci. 2008 Autumn. 38(4):390-2. [Medline].
Persing DH, Mathiesen D, Marshall WF, Telford SR, Spielman A, Thomford JW, et al. Detection of Babesia microti by polymerase chain reaction. J Clin Microbiol. 1992 Aug. 30(8):2097-103. [Medline]. [Full Text].
Krause PJ, Spielman A, Telford SR 3rd, et al. Persistent parasitemia after acute babesiosis. N Engl J Med. 1998 Jul 16. 339(3):160-5. [Medline].
Cunha BA, Cohen YZ, McDermott B. Fever of unknown origin (FUO) due to babesiosis in a immunocompetent host. Heart Lung. 2008 Nov-Dec. 37(6):481-4. [Medline].
Krause PJ, Lepore T, Sikand VK, Gadbaw J Jr, Burke G, Telford SR 3rd, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000 Nov 16. 343(20):1454-8. [Medline].
Vyas JM, Telford SR, Robbins GK. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. Clin Infect Dis. 2007 Dec 15. 45(12):1588-90. [Medline].
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis. 2010 Feb 1. 50(3):381-6. [Medline].
Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008 Feb 1. 46(3):370-6. [Medline].
Cushing M, Shaz B. Transfusion-transmitted babesiosis: achieving successful mitigation while balancing cost and donor loss. Transfusion. 2012 Jul. 52(7):1404-7. [Medline].
Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011 Oct 18. 155(8):509-19. [Medline].
Hildebrandt A, Gray JS, Hunfeld KP. Human babesiosis in Europe: what clinicians need to know. Infection. 2013 Dec. 41(6):1057-72. [Medline].
Kavanaugh MJ, Decker CF. Babesiosis. Dis Mon. 2012 Jun. 58(6):355-60. [Medline].
Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012 Jun 21. 366(25):2397-407. [Medline].
Wroblewski HA, Kovacs RJ, Kingery JR, Overholser BR, Tisdale JE. High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis. Antimicrob Agents Chemother. 2012 Aug. 56(8):4495-9. [Medline]. [Full Text].